Advancements in Alzheimer’s Research: UMons and the Stop Alzheimer Foundation

Recent collaborative efforts between the University of Mons (UMons) and the Stop Alzheimer Foundation are driving significant progress in understanding and addressing Alzheimer’s disease in Belgium. These initiatives focus on both pharmacological and non-pharmacological approaches to improve the quality of life for patients and their families.

Funding and Research Focus

The Stop Alzheimer Foundation has committed substantial funding to research projects at UMons, totaling over €400,000 in recent grants. This investment supports multiple research teams dedicated to unraveling the complexities of Alzheimer’s disease.

Reducing Behavioral Disturbances

A key project, led by Professor Laurent Lefebvre, received €100,051 in funding to develop strategies for reducing behavioral disturbances in patients with moderate to severe Alzheimer’s disease. Stop Alzheimer recognizes that these disturbances significantly impact both patients and caregivers, and non-medication solutions are crucial.

Professor Lefebvre’s team is pioneering the use of artificial intelligence to analyze patient language in various emotional contexts. This tool, named AECEL, aims to better understand the cognitive abilities that remain in patients and how emotions influence their expression. The goal is to improve communication and reduce agitation, aggression, and confusion.

Investigating Cerebral Inflammation

Another significant grant of €300,000 was awarded to researcher Carmen Burtea to investigate the role of cerebral inflammation in the progression of Alzheimer’s disease. UMons Innovation Network reports that Burtea’s research focuses on a key enzyme involved in inflammatory processes within the brain. Previous perform by her team has identified a potential approach to modulate this enzyme’s activity, and the modern funding will be used to confirm its effectiveness and move towards potential therapeutic applications.

Improving Cognitive Testing

Researchers at the University of Liège, including Jérémy Gardette, are working to refine cognitive tests to better identify dysfunctions in the brain regions initially affected by Alzheimer’s disease.

The Scope of Alzheimer’s Disease in Belgium

Alzheimer’s disease currently affects over 220,000 people in Belgium. UMons highlights the urgent need for effective treatments and supportive care, especially given the limited efficacy and accessibility of current medications.

Looking Ahead

The collaborative efforts between UMons and the Stop Alzheimer Foundation represent a significant step forward in the fight against Alzheimer’s disease. By focusing on both pharmacological and non-pharmacological interventions, these research projects aim to improve the lives of patients and their families, even in the absence of a definitive cure.